Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc.
Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN ) investors who purchased securities between September 2, 2016 and August 13, 2019, inclusive (the Class Period).
- Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN ) investors who purchased securities between September 2, 2016 and August 13, 2019, inclusive (the Class Period).
- Myriad also disclosed that the FDA requested changes to the GeneSight test offering after Myriad had provided the FDA with clinical evidence and other information to support GeneSight Psychotropic.
- If you purchased or otherwise acquired Myriad securities during the class period, you may move the Court no later than November 26, 2019 to request appointment as lead plaintiff in this putative class action lawsuit.
- To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.